Cagnazzo f, ahmed r, lefevre ph, derraz i, dargazanli c, gascou g, riquelme c, frandon j, bonafe a, costalat v.
Flow modification on the internal carotid artery bifurcation region and a1 segment after m1-internal carotid artery flow diverter deployment.
Journal of neurointervent surgery.
2020;12:1226¿1230.
Doi:10.
1136/neurintsurg-2020-016051.
Age: this value is the average age of the patients reported in the article as specific patients could not be identified.
Sex: this value reflects the gender of the majority of the patients reported in the article as specific patients could not be identified.
If information is provided in the future, a supplemental report will be issued.
|
Cagnazzo f, ahmed r, lefevre ph, derraz i, dargazanli c, gascou g, riquelme c, frandon j, bonafe a, costalat v.
Flow modification on the internal carotid artery bifurcation region and a1 segment after m1-internal carotid artery flow diverter deployment.
Journal of neurointervent surgery.
2020;12:1226¿1230.
Doi:10.
1136/neurintsurg-2020-016051.
Clinical and hemodynamic consequences of flow diverters extending from the m1 to the internal carotid artery (ica), covering the a1 segment, have rarely been investigated.
The purpose of this article was to provide angiographic and clinical data about flow modifications on the covered a1.
The authors reviewed 42 cases of a1 arteries covered with a single device.
Of the 42 patients, the average age was 54 years, 35 were female and 7 were male.
Flow diverters were successfully deployed from the m1 to the ica segment in all patients.
The mean diameter of the covered a1 was 2.
1 mm (median 2.
2 mm, sd 0.
4, range 1.
2¿3.
5 mm).
Immediately after flow diversion deployment, 20 (47.
6%) covered a1 showed slow flow because of the flow compensation from the contralateral side through a patent acoma.
No cases of immediate occlusion were recorded.
The overall rate of complications related to the m1-ica flow diversion was 4.
7%, with 2.
3% morbidity.
The article does not state any technical issues during use of the pipeline.
The following intra- or post-procedural outcomes were noted: after prasugrel discontinuation at 6 months, one patient developed a basal ganglia infarct related to the coverage of the m1 perforators; the patient partially recovered with an mrs score of 1 at the 12 month follow-up.
One patient had an acute instant thrombosis which completely resolved after treatment with abciximab, without any neurological sequelae.
|